Biotech Values

[vinmantoo]

I thought paxlovid did see a benefit in VL but it may not have been stat stig and obviously it was in high risk patients who are going to clear virus far slower

I don't think they showed significance with regards to viral load, but I am pretty sure Paxlovid failed to statistically reduce symptoms.

To see any clinical improvement in a low risk population is a win I think - this definitely warrants progressing to a phase 3 non-inferiority trial in high risk patients vs paxlovid IMO

Agreed!